| Literature DB >> 33420682 |
Roberto Martín-Asenjo1, John Gregson2, Xavier Rossello2,3,4, Frans Van de Werf5, Jesús Medina6, Nicolas Danchin7, Stuart Pocock2,4, Héctor Bueno8,9,10,11.
Abstract
Antithrombotic drug use for acute coronary syndromes (ACS) varies considerably. The number of antithrombotic drugs (excluding oral anticoagulants) used pre- and in-hospital was recorded in ACS survivors enrolled at hospital discharge in the long-tErm follow-uP of antithrombotic management patterns In acute CORonary syndrome patients (EPICOR) registry ( NCT01171404 ), a prospective cohort study. Among 10,568 patients, the number of antithrombotic drugs used early/patient ranged from 0 to 8 (interquartile range = 3-4). Overall, 250 patients (2.4%) experienced ≥ 1 in-hospital ischemic event and 343 (3.2%) ≥ 1 non-fatal bleeding event. While there was no difference in the rate of ischemic events (p = 0.75 for-trend) according to the number of antithrombotic drugs, a significantly higher incidence of non-fatal bleeds was observed (p < 0.0001 for-trend), with OR = 1.68 (95%CI = 1.51-1.88) per additional antithrombotic drug, which remained after adjustment by patient characteristics. In conclusion, careful balancing of the short-term risks for ischemic and bleeding events should be considered when adding new antithrombotic drugs.Entities:
Keywords: Acute coronary syndrome; Antithrombotic drugs; Bleeding; Cardiac risk factors and prevention; Quality and outcomes of care
Mesh:
Substances:
Year: 2021 PMID: 33420682 DOI: 10.1007/s12265-020-10094-5
Source DB: PubMed Journal: J Cardiovasc Transl Res ISSN: 1937-5387 Impact factor: 4.132